◼ Archived
Business
🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
5sources
5articles
3velocity
+0%since first seen
21d agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (5)
- JATT II Acquisition to Merge With Talawar Tx; JATT to Become Subsidiary in SPAC Deal TradingView · 21d ago
- Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease Endpoints News · 21d ago
- Talawar bets bispecific approach can shake up eczema market statnews.com · 21d ago
- 'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset Fierce Biotech · 21d ago
- Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases PR Newswire · 21d ago
Related trends
▲ Peaking
Business
Oil tops $90 as Middle East fighting escalates
▲ Peaking
Business
Samsung Debuts Galaxy Card With 5% Cash Back to Take On Apple Card
Samsung enters the U.S. credit market with the Galaxy Card, offering 5% cash back to compete directly with Apple Card.
▲ Peaking
Business
The bar for Tesla earnings is sky-high. Here's why and how options traders can capitalize
▲ Peaking
Business
Morning Bid: Oil trumps AI
▲ Peaking
Business
The secret Trump administration battle to fight Chinese AI
▲ Peaking
Business